Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

Zymeworks (Nasdaq: ZYME), a clinical-stage biotech developing antibody-based therapies for cancer and immune diseases, has ...

Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, ...

A biotech company integrating of AI and synthetic biology to design safer and more effective antibody therapeutics.

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Russian public procurements of drugs based on the active ingredient semaglutide, which is an original drug from Denmark’s ...

Adding to the list of pharma majors starting or expanding production in the USA, Swiss pharma giant Roche (ROG: SIX) today announced that it will invest $50 billion into America in the next five years ...

South Korea-based biotech firms 1ST Biotherapeutics and LigaChem Biosciences (Kosdaq: 141080) have entered a strategic partnership to co-develop next-generation antibody-drug conjugates and small ...